| Oct 30 |
Carisma Therapeutics Announces Changes to its Board of Directors
|
| Oct 4 |
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
|
| Sep 10 |
Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases
|
| Sep 10 |
Moderna, Carisma deal expands with autoimmune targets
|
| Sep 10 |
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
|
| Aug 13 |
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
|
| Aug 8 |
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Carisma Therapeutics GAAP EPS of -$0.27 beats by $0.03, revenue of $9.2M beats by $5.28M
|
| Aug 8 |
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 6 |
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
|
